Madison Vaccines Closes $8 Million Series A Financing
1/13/2014 10:19:30 AM
MADISON, Wisc.--(BUSINESS WIRE)--Madison Vaccines Incorporated (MVI), a clinical stage biopharmaceutical company focused on advancing innovative therapies for prostate cancer, today announced an initial close of an $8 million Series A financing. The round was led by Venture Investors, LLC, and joined by Wisconsin Alumni Research Foundation (WARF), Venture Management, LLC (VM), the State of Wisconsin Investment Board (SWIB), and others. The proceeds will support ongoing development of MVI’s pipeline, including completion of an expanded Phase 2 clinical trial for MVI-816 in non-metastatic prostate cancer patients with rapidly rising PSA, before the need for surgical or chemical castration (androgen deprivation therapy or ADT). These are patients with the highest risk of developing bone or other metastases after their initial prostate cancer therapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by